Navigation Links
Singulex Teams With Wyeth Pharmaceuticals to Translate Pre-Clinical Biomarker Research Into Clinical Study Design
Date:11/27/2007

HAYWARD, Calif., Nov. 27 /PRNewswire/ -- Singulex Inc. today announced that it is collaborating with researchers at Wyeth Research to develop immunoassays on the company's Erenna(TM) system. Singulex has installed the Erenna system at Wyeth as part of its Erenna Technology Access Program (ETAP) and has begun optimizing assays that will allow Wyeth to accurately and precisely measure specific biomarkers in human blood.

"Biomarkers play an important role in the evaluation of compounds in both drug discovery and development, and we are keenly interested in applying new and improved technologies in the measurements of biomarkers," said Ole Vesterqvist, Ph.D., senior director of the Biomarker Laboratory in Clinical Translational Medicine at Wyeth. "For example, with the right biomarker and technology, one can study the effects of a therapeutic intervention in clinical studies. However, many biomarkers are present in human blood at extremely low concentrations, making it difficult to accurately and precisely measure. Singulex has provided us with a new technology for detection of biomarkers at very low concentrations and we are currently validating several assays in our laboratory that should help us guide our clinical programs."

Singulex's proprietary advanced biomarker detection technologies and optimized immunoassays are incorporated into Erenna, the company's flagship biomarker detection platform system. Erenna and accompanying assays are designed to measure very low levels and small changes of protein biomarkers across a variety of biological samples from multiple species. Singulex was the first to identify and quantify normal levels and small changes of cardiac troponin I, a protein biomarker used to detect cardiotoxicity and heart attacks, in human plasma.

"Singulex's technology extends the clinical utility of new and existing biomarkers by removing the limits of detection," said Philippe Goix, Ph.D., president and CEO of Singulex. "The ability to detect normal and deviations from normal levels of biomarkers will enable better determination of therapeutic index for drug developers and researchers and help shorten the time to select and develop new therapies."

About Singulex

Singulex develops and commercializes innovative technology solutions that enable disease understanding and management for life science researchers and clinicians. Utilizing proprietary quantitative single molecule detection technology, Singulex develops customized biomarker diagnostic systems that can detect and quantify normal and abnormal protein biomarkers in a variety of biological samples with extreme sensitivity and accuracy. Singulex is currently conducting several pilot studies with academic and molecular diagnostic partners to validate the company's commercial digital molecule detection platform, the Erenna(TM) Immunoassay System. Singulex's research and development facilities are located at the Center for Emerging Technologies in St Louis, Missouri, and the company's commercial operations are based in Hayward, California. To learn more about Singulex, please visit us at http://www.singulex.com.

About ETAP

The Erenna(TM) Technology Access Program (ETAP) offers select clients the opportunity to use Singulex's flagship Erenna system to improve and validate their vital immunoassays, adding as much as 1-3 logs of improvement in sensitivity and providing less than 20% coefficient of variability. ETAP includes the Erenna system, which is designed to detect and count single molecules, customized immunoassay development services, reagents, software and direct and personal client service.


'/>"/>
SOURCE Singulex Inc.
Copyright©2007 PR Newswire.
All rights reserved

Related biology news :

1. Bacteria from sponges make new pharmaceuticals
2. Researchers develop liquid crystal pharmaceuticals to fight cancer and other diseases
3. NMR researchers unlock hydrogens secrets to spot polymorphism in pharmaceuticals
4. A search for biomarkers for early detection of colorectal cancer
5. Research shows skeleton to be endocrine organ
6. Newly created cancer stem cells could aid breast cancer research
7. Dominant cholesterol-metabolism ideas challenged by new research
8. Researchers identify proteins involved in new neurodegenerative syndrome
9. Texas researchers and educators head for Antarctica
10. MGH researchers describe new way to identify, evolve novel enzymes
11. University of Pennsylvania researchers develop formula to gauge risk of disease clusters
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:2/2/2016)... , Feb. 2, 2016 Technology Enhancements Accelerate Growth ... analysis of the digital and computed radiography markets in ... , and Indonesia (TIM). It ... market size, as well as regional market drivers and ... discusses market penetration and market attractiveness, both for digital ...
(Date:2/1/2016)...  Today, the first day of American Heart Month, ... a first of its kind workplace health solution that ... the first application of Watson ... and Welltok will create a new offering that combines ... delivered on Welltok,s health optimization platform. The effort is ...
(Date:1/25/2016)... , Jan. 25, 2016   Unisys Corporation (NYSE: ... John F. Kennedy (JFK) International Airport, New York City ... (CBP) identify imposters attempting to enter the United States ... to them. pilot testing of the system at ... three terminals at JFK during January 2016. --> pilot ...
Breaking Biology News(10 mins):
(Date:2/12/2016)... (PRWEB) , ... February 12, 2016 , ... Global ... to launch its new stem cell treatment center in Quito, Ecuador, Feb. 24-March 6, ... to patients from around the world. , Global Stem Cells Group CEO Benito ...
(Date:2/12/2016)... FRANCISCO , February 12, 2016 ... Medicine Efforts by Enabling Scientific Understanding of Complex ... and Rare Diseases --> ... genomic diagnostics in South Asia and a leading provider ... would contribute $10 million to the GenomeAsia 100K ...
(Date:2/11/2016)... 11, 2016  Bioethics International, a not-for-profit organization focused on ... marketed and made accessible to patients around the world, today ... named the publication of the Good Pharma Scorecard ... also featured as one of BMJ Open ,s ,Most ... that are most frequently read. Ed Sucksmith , ...
(Date:2/11/2016)... , February 11, 2016 ... Corporation ("PositiveID" or "Company") (OTCQB: PSID), a life ... today that its Thermomedics subsidiary, which markets the ... its growth plan in January 2016, including entering ... increasing sequential monthly sales growth, and establishing several ...
Breaking Biology Technology: